Bacillus clausii UBBC-07 Probiotic for IBD Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) are inadequate in effectively managing symptoms and often come with side effects, and there is a need for a more sustainable approach to modulating the gut microbiota to reduce inflammation.
Innovation Solution
A probiotic formulation comprising Bacillus clausii UBBC-07 is administered to patients, which modulates the gut microbiota profile, decreases inflammation, and is used in conjunction with standard medical treatment to alleviate symptoms of IBD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for IBD are used, then inflammation can be suppressed, but side effects increase and symptom management remains inadequate
Solution Approach 1:
The probiotic composition acts as an intermediary agent that modulates the gut microbiota to reduce inflammation. Instead of directly suppressing inflammation with drugs that cause side effects, the probiotics work through the microbiome as a mediator, restoring microbial balance and indirectly reducing inflammatory responses, thereby achieving symptom management with fewer adverse effects
Solution Approach 2:
The probiotic formulation enables the gut microbiota to self-regulate and restore its own balance. By introducing beneficial Bacillus clausii strains, the system activates the body's natural ability to maintain microbial homeostasis, allowing the microbiome to self-correct dysbiosis and reduce inflammation without requiring continuous external intervention with potentially harmful medications
2Reliability
If probiotic formulation is administered to modulate gut microbiota, then inflammation decreases and beneficial bacteria increase, but treatment duration and dosage optimization are required
Solution Approach 1:
The patent optimizes treatment parameters including dosage (1-10 billion CFU per day), administration frequency (1-2 times daily), and treatment duration (4-12 weeks) to achieve effective inflammation reduction. By systematically determining and applying these optimized parameters, the treatment achieves reliable therapeutic effects while minimizing unnecessary treatment time through evidence-based dosing protocols
3Quantity of substance
If Bacillus clausii is administered to increase beneficial commensal bacteria, then gut microbiota profile improves, but survival of the probiotic in the GI tract must be ensured
Solution Approach 1:
The probiotic Bacillus clausii strains are formulated with protective mechanisms that enable them to survive the harsh gastrointestinal environment. The spore-forming nature of Bacillus provides a protective shell that allows the bacteria to withstand stomach acid and bile, ensuring sufficient viable cells reach the gut to colonize and increase beneficial commensal bacteria populations
Solution Approach 2:
The probiotic formulation uses high doses of spore-forming bacteria that are designed to temporarily colonize the gut, perform their beneficial function of modulating microbiota and reducing inflammation, and then naturally die off. This approach ensures sufficient survival through the GI tract to achieve therapeutic effects without requiring long-term persistence of the probiotic organisms themselves
Data Source
AI summary
The current invention discloses the method of treating, preventing and/or ameliorating Inflammatory Bowel Disease in patients by administering a probiotic composition comprising Bacillus clausii. The current invention discloses a method for, prevention and/or treatment, and amelioration of symptoms of Inflammatory Bowel Disease by use of Bacillus clausii, which modulates the microbiome in the gastro-intestinal tract and decreases inflammation in the patients.